Edmonton's haematology specialists manage severe aplastic anaemia patients requiring high-dose Eltrombopag combination therapy. Rompag 50mg provides substantial savings versus brand Revolade for Alberta patients.
Clinical data shows adding Eltrombopag to standard immunosuppressive therapy produces complete haematologic responses in the majority of previously untreated severe aplastic anaemia patients.
|
FAQ: How long does aplastic anaemia treatment with
Rompag typically continue? Treatment duration varies
based on response, but many patients continue Eltrombopag for at least 6
months as part of combination therapy, with some continuing longer if needed
to maintain blood counts. Your haematologist will assess response through
regular blood counts and may attempt gradual dose reduction once a stable,
sustained response is achieved. |
